Download PDF
Pharmacopsychiatry 2010; 43(5): 166-173
DOI: 10.1055/s-0030-1249049
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Impact of Escitalopram on Nocturnal Sleep, Day-Time Sleepiness and Performance Compared to Amitriptyline: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects

J. P. Doerr1 , K. Spiegelhalder1 , F. Petzold1 , B. Feige1 , V. Hirscher1 , R. Kaufmann1 , D. Riemann1 , U. Voderholzer1 , 2
  • 1Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany
  • 2Medical-Psychosomatic Clinic Roseneck, Prien, Germany
Further Information

Publication History

received 26.08.2009 revised 02.12.2009

accepted 17.12.2009

Publication Date:
05 July 2010 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: Antidepressant drugs vary in their effects on sleep, day-time sedation and performance. Up to now, no data are available for either escitalopram (ESCIT) or amitriptyline (AMI), measuring these by an objective test, such as the multiple sleep latency test (MSLT).

Subjects and Methods: We therefore investigated the impact of a single evening dose of 10 mg ESCIT on polysomnographically recorded nocturnal sleep, day-time sleepiness and performance in comparison to 75 mg AMI and placebo (PLAC) in healthy male subjects.

Results: Both antidepressants significantly suppressed REM sleep (p<0.001). Although polysomnographically measured sleep continuity was impaired after ESCIT (p=0.006), subjective estimates of sleep parameters did not differ. Periodic limb movements (PLMS) were increased after AMI (p<0.001) but not after ESCIT. Processing speed and performance were enhanced after ESCIT compared with AMI (p=0.011), but not with PLAC. Next-day alertness was significantly impaired by AMI (p=0.012), but not by ESCIT. Mean day-time sleep onset latencies increased significantly after evening ESCIT (p<0.001). In contrast, AMI led to a pronounced increase of day-time sleepiness (p=0.007).

Discussion: This study demonstrates that single evening doses of either AMI or ESCIT exhibit different effects on next-day vigilance and alertness in terms of a slightly stimulating effect of ESCIT and a significant reduction after AMI.

References

  • 1 Armitage R, Trivedi M, Rush AJ. Fluoxetine and oculomotor activity during sleep in depressed patients.  Neuropsychopharmacology. 1995;  12 159-165
    CrossrefPubMedGoogle Scholar
  • 2 Atlas, scoring rules. Recording and scoring leg movements.  Sleep. 1991;  16 749-759
    PubMedGoogle Scholar
  • 3 Bakshi R. Fluoxetine and restless legs syndrome.  J Neurol Sci. 1996;  142 151-152
    CrossrefPubMedGoogle Scholar
  • 4 Billiard M, Dauvilliers Y. Idiopathic hypersomnia.  Sleep Med Rev. 2001;  5 349-358
    CrossrefPubMedGoogle Scholar
  • 5 Brickenkamp R. Test d2 – Aufmerksamkeits-Belastungs-Test. Göttingen, Hogrefe Verlag; 1994
    Google Scholar
  • 6 Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.  J. Clin. Psychiatry. 2002;  63 331-336
    CrossrefPubMedGoogle Scholar
  • 7 Colonna L, Reines EH, Andersen HF. A randomized,double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive patients with major depressive disorder.  Curr Med Res Opin. 2005;  21 1659-1668
    CrossrefPubMedGoogle Scholar
  • 8 DeVane CL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.  Cell Mol Neurobiol. 1999;  19 443-466
    CrossrefPubMedGoogle Scholar
  • 9 Dorsey CM, Lukas SE, Cunningham SL. Fluoxetine induced sleep disturbance in depressed patients.  Neuropsychopharmacology. 1996;  14 437-442
    CrossrefPubMedGoogle Scholar
  • 10 Fairweather D, Kerr J, Hilton S. et al . A placebo-controlled double-blind evaluation of the pharmacodynamics of fengabine vs amitriptyline following single and multiple doses in elderly volunteers.  Br J Pharmacol. 1993;  35 278-283
    PubMedGoogle Scholar
  • 11 Feige B, Voderholzer U, Riemann D. et al . Independent sleep EEG slow-wave and spindle band dynamics associated with 4 weeks of continuous application of short-half-life hypnotics in healthy subjects.  Clin Neurophysiol. 1999;  110 1965-1974
    CrossrefPubMedGoogle Scholar
  • 12 Fischer-Cornelssen K, Ferner U, Steiner H. [Multifocal psychopharmaceutic testing (“Multihospital trial”.)].  Arzneimittelforschung. 1974;  24 1706-1724
    PubMedGoogle Scholar
  • 13 Gillin JC, Jernajczyk W, Valladares-Neto DC. et al . Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers.  Psychopharmacology (Berl). 1994;  116 433-436
    CrossrefPubMedGoogle Scholar
  • 14 Görtelmeyer R. Schlaffragebogen SF-A und SF-B; in Collegium Internationale Psychiatriae Scalarum (CIPS). Internationale Skalen für Psychiatrie. Weinheim, Beltz; 1981
    Google Scholar
  • 15 Grimsley S, Jahn M. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors.  Clin Pharmacy. 1992;  11 930-957
    PubMedGoogle Scholar
  • 16 Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system.  Nat Rev Neurosci. 2003;  4 121-130 ; 12: 537–549
    PubMedGoogle Scholar
  • 17 Herberg K. Verkehrs- und Alltagssicherheit bei Medikation mit Citalopram.  Psychopharmakotherapie. 2001;  18 81-88
    PubMedGoogle Scholar
  • 18 Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance.  Int Clin Psychopharmacol. 2000;  15 305-318
    CrossrefPubMedGoogle Scholar
  • 19 Hobson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups.  Science. 1975;  189 (4196) 55-58
    CrossrefPubMedGoogle Scholar
  • 20 Hobson JA, Pace-Schott EF, Stickgold R. Dreaming and the brain: toward a cognitive neuroscience of conscious states.  Behav Brain Sci. 2000;  23 793-842 ; discussion 904-1121
    CrossrefPubMedGoogle Scholar
  • 21 Hornyak M, Voderholzer U, Riemann D. Treatment of depression in patients with restless legs syndrome: what is evidence-based?.  Sleep Med. 2006;  7 301-302
    CrossrefPubMedGoogle Scholar
  • 22 Jones DM, Allen EM, Griffiths AN. et al . Human cognitive function following binedaline (50 mg and 100 mg) and imipramine (75 mg): results with a new battery on tests.  Psychopharmacology. 1986;  89 198-202
    CrossrefPubMedGoogle Scholar
  • 23 Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.  J Clin Psychiatry. 1997;  58 146-152
    CrossrefPubMedGoogle Scholar
  • 24 Koppitz EM. The visual aural and digit span test. New York, Grune & Stratton; 1977
    Google Scholar
  • 25 Kryger MH, Roth T, Dement WC. Principles and practice of sleep medicine. 4th edition. Philadelphia, Saunders; 2004
    Google Scholar
  • 26 Lader M, Melhuish A, Frcka G. et al . The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects.  Eur J Clin Pharmacol. 1986;  31 183-190
    CrossrefPubMedGoogle Scholar
  • 27 Lader M, Andersen HF, Baekdal T. The effect of escitalopram on sleep problems in depressed patients.  Hum Psychopharmacol. 2005;  20 349-354
    CrossrefPubMedGoogle Scholar
  • 28 Lawlor BA, Newhouse PA, Balkin TJ. et al . A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers.  Biol. Psychiatry. 1991;  29 281-286
    CrossrefPubMedGoogle Scholar
  • 29 Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.  Int Clin Psychopharmacol. 2003;  18 211-217
    CrossrefPubMedGoogle Scholar
  • 30 Monaca C, Boutrel B, Hen R. et al . 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice.  Neuropsychopharmacology. 2003;  28 850-856
    PubMedGoogle Scholar
  • 31 Murck H, Nickel T, Künzel H. et al . State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine.  Neuropsychopharmacology. 2003;  28 348-358
    CrossrefPubMedGoogle Scholar
  • 32 Nathan PJ, Sitaram G, Stough C. et al . Serotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor.  Behav Pharmacol. 2000;  11 639-642
    CrossrefPubMedGoogle Scholar
  • 33 Oberndorfer S, Saletu-Zyhlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality.  Neuropsychobiology. 2000;  42 69-81
    CrossrefPubMedGoogle Scholar
  • 34 Oswald I, Adam K. Effects of paroxetine on human sleep.  Br J Clin Pharmacol. 1986;  22 97-99
    PubMedGoogle Scholar
  • 35 Ramaekers JG, Muntjewerff ND, O’Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance.  Br J Clin Pharmacol. 1995;  39 397-404
    PubMedGoogle Scholar
  • 36 Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers.  Am J Epidemiol. 1992;  136 873-883
    CrossrefPubMedGoogle Scholar
  • 37 Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Washington, Government Printing Office; 1968
    Google Scholar
  • 38 Riedel WJ, Eikmans K, Heldens A. et al . Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment.  J Psychopharmacol. 2005;  19 12-20
    CrossrefPubMedGoogle Scholar
  • 39 Riemann D, Voderholzer U, Cohrs S. et al . Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study.  Pharmacopsychiatry. 2002;  35 165-174
    Google Scholar
  • 40 Roeschke J, Kögel P, Schlösser R. et al . Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects.  Psychopharmacology. 1997;  132 44-49
    CrossrefPubMedGoogle Scholar
  • 41 Rosenberg C, Damsbo N, Fuglum E. et al . Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study.  Int Clin Psychopharmacol. 1994;  9 (S 01) 41-48
    PubMedGoogle Scholar
  • 42 Rottach KG, Schaner BM, Kirch MH. et al . Restless legs syndrome as side effect of second generation antidepressants.  J Psychiatr Res. 2008;  43 70-75
    CrossrefPubMedGoogle Scholar
  • 43 Saletu B. Psychopharmaka, Gehirntätigkeit und Schlaf Neurophysiologische Aspekte der Psychopharmakologie und Pharmakopsychiatrie.  Bibl Psychiatr Basel, Karger. Vol. 155, 1976
    PubMedGoogle Scholar
  • 44 Saletu B, Frey R, Krupka M. et al . Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities.  Sleep. 1991;  14 439-447
    PubMedGoogle Scholar
  • 45 Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers.  J Clin Psychiatry. 1997;  58 348-350
    CrossrefPubMedGoogle Scholar
  • 46 Sharpley A, Cowen P. Effect of pharmacologic treatments on the sleep of depressed patients.  Biol Psychiatry. 1995;  15 85-98
    PubMedGoogle Scholar
  • 47 Staner L, Kerkhofs M, Detroux D. et al . Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression.  J. Sleep. 1995;  18 470-477
    PubMedGoogle Scholar
  • 48 van Bemmel AL, van den Hoofdakker RH, Beersma DG. et al . Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram.  Psychopharmacology (Berl). 1993;  113 225-230
    CrossrefPubMedGoogle Scholar
  • 49 Vasar V, Appelberg B, Rimón R. et al . The effect of fluoxetine on sleep: a longitudinal, double-blind polysomnographic study of healthy volunteers.  Int Clin Psychopharmacol. 1994;  9 203-206
    CrossrefPubMedGoogle Scholar
  • 50 Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.  Int Clin Psychopharmacol. 2002;  17 95-102
    CrossrefPubMedGoogle Scholar
  • 51 Wilson SJ, Bailey JE, Alford C. et al . Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers.  J Psychopharmacol. 2000;  14 378-386
    CrossrefPubMedGoogle Scholar
  • 52 Wilson SJ, Bailey JE, Rich AS. et al . Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram.  Eur Neuropsychopharmacol. 2004;  14 367-372
    CrossrefPubMedGoogle Scholar
  • 53 Wingen M, Bothmer J, Langer S. et al . Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial.  J Clin Psychiatry. 2005;  66 436-443
    CrossrefPubMedGoogle Scholar
  • 54 Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep.  Biol. Psychiatry. 2005;  15; 58 (6) 510-514
    PubMedGoogle Scholar
  • 55 Zimmermann P, Fimm B. Testbatterie zur Erfassung von Aufmerksamkeitsstörungen. Version 1.02. Freiburg: Psytest; 1993
    Google Scholar

Correspondence

J. P. DoerrMD 

Department of Psychiatry and

Psychotherapy

University Medical Center

Freiburg

Hauptstraße 5

79104 Freiburg

Germany

Phone: +49/761/270 6625

Fax: +49/761/270 6528

Email: john-peter.doerr@uniklinik-freiburg.de

      >